Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048

BACKGROUND: In renal cell carcinoma (RCC), angiopoietin (Ang) 2 is elevated at the time of progression on anti-vascular endothelial growth factor (VEGF) therapy and may contribute to resistance. OBJECTIVE: We tested trebananib, an Ang 1 and 2 neutralizing peptibody in patients with RCC progressing o...

Descripción completa

Detalles Bibliográficos
Autores principales: Semrad, Thomas J, Groshen, Susan, Luo, Chunqiao, Pal, Sumanta, Vaishampayan, Ulka, Joshi, Monika, Quinn, David I., Mack, Philip C., Gandara, David R., Lara, Primo N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400131/
https://www.ncbi.nlm.nih.gov/pubmed/30854497
http://dx.doi.org/10.3233/KCA-180041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400131/
https://www.ncbi.nlm.nih.gov/pubmed/30854497
http://dx.doi.org/10.3233/KCA-180041

Ejemplares similares